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Background: Chronic treatment with currently available oral hypoglyemic medications may result in a differential
effect on the clinical presentation of diabetic patients with acute coronary syndrome (ACS).
Methods: We evaluated presentation characteristics and the risk for in-hospital complications and 30-day major
adverse cardiovascular events (MACE) among 445 patients with diabetes mellitus enrolled in the Acute Coronary
Syndrome Israeli Survey (ACSIS) 2010. Patients were categorized into 3 groups according to glucose lowering
medications at time of admission for ACS: 1) DPP 4 inhibitors (as monotherapy or in combination; DPP4i), 2)
Metformin (monotherapy or in combination, excluding DPP4i) and 3) other oral hypoglycemics.
Results: Patients in the DPP4i group displayed similar baseline clinical characteristics to the other 2 groups, with
the exception of a younger age and a lower frequency of prior coronary heart disease and chronic renal failure.
Medical therapy with DPP4i was associated with a significantly lower in-hospital complication rate (post MI angina,
re-infarction, pulmonary edema, infections, acute renal failure and better KILLIP class) (9.7%), lower rates of 30-day
MACE (12.9%) and a shorter hospital stay (5.4 ± 3.8 days) as compared with patients treated with metformin
(24.4%, 31.6% and 5.6 ± 5.0 days respectively) or other oral hypoglycemic drugs (45.5%, 48.5% and 7.5 ± 6.5 days
respectively). Consistently, multivariate logistic regression modeling revealed that treatment with DPP4i was
associated with a lower risk for in-hospital complications (OR = 0.129, p = 0.002) and 30-day MACE (OR = 0.157,
p = 0.002) compared with other oral hypoglycaemic therapy.
Conclusions: Our data suggests that chronic treatment with DPP4i may have cardioprotective effects in diabetes
patients presenting with acute coronary syndrome.
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The prevalence of diabetes is increasing worldwide, and
it is estimated that 7.7% or 439 million of the global
adult population will have diabetes by 2030 [1]. The aim
of diabetes treatment is to reduce glucose levels and to
achieve the recommended HbA1C level of <7%, in order
to reduce the occurrence of vascular complications [2].* Correspondence: leibovitz@wolfson.health.gov.il
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reproduction in any medium, provided the orControlling glucose levels is difficult and requires usage
of glucose lowering medications in most if not all cases.
This demand for anti-diabetes medications has driven
the pharmaceutical industry to develop new drugs.
Several new anti-diabetes agents were approved for treat-
ment due to their glucose lowering effect, but without
proof of reduction of hard end-points, such as major ad-
verse cardiovascular events (MACE). One of the drugs ap-
proved for diabetes control was Rosiglitazone, a PPAR
gamma agonist that was shown to significantly improve
glucose levels among patients with diabetes [3]. This drugal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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warnings for possible cardiovascular complications [4].
Two other drug families that were recently approved
for treatment of diabetes mellitus are the Glucagone like
Peptide-1 (GLP-1) analogues and Di Peptidyl Peptidase
IV (DPP4) inhibitors, both act via the incretin pathway.
Glucagone like Peptide-1 enhances the secretion of insulin
from pancreatic beta cells following meals, as well as pre-
vent apoptosis of these cells via sub-cellular pathways such
as JNK [5]. These peptides have a short half-life, and are
metabolized by the enzyme DPP-4 to their inactive form.
The GLP-1 analogues are peptides that are resistant to
the activity of DPP-4, and therefore have a longer half-
life and enhanced activity. DPP-4 inhibitors (DPP4i) in-
crease the half-life of the incretins by preventing their
degradation. Both drug families have been shown to
have beneficial effects on blood glucose and enhance the
control rate of diabetes [6,7]. Recent data suggest that
DPP4i may have antithrombotic and anitinflmmatory ef-
fects [8], and thus may be protective in patients who
present with acute coronary syndrome (ACS). However,
there are limited data regarding the effects of different
classes oral hypoglycemic medications on the clinical
presentation of ACS.
Accordingly, the purpose of this study was to examine
the effects of glucose lowering medications on the type
and severity of myocardial damage, in-hospital complica-
tions and 30-day MACE among diabetes patients admit-
ted to the hospital with acute coronary syndrome.
Methods
The parameters in this study were derived from the Acute
Coronary Syndrome Israeli Survey (ACSIS) 2010, a bi-
annual nationwide survey of acute coronary syndrome pa-
tients that were admitted to all 26 public hospitals in Israel
during a 2 month period of March-April 2010. Methods
on data acquisition are specified elsewhere [9].
Included in this sub-analysis were all patients diag-
nosed with type 2 diabetes mellitus that received oral
hypoglycemic medications. Excluded were patients who
were on chronic insulin treatment (all types either as
monotherapy or in combination with oral hypoglycemic
medications) and those newly diagnosed with diabetes
mellitus during the admission associated with the coron-
ary event. Duration of treatment with oral hypoglycemic
medication prior to hospitalization was not recorded.
The ACSIS survey is a nationwide survey conducted in
several hospitals across Israel. The study was approved
by each of the local IRB’s as an observational study, pre-
cluding the need for informed consent.
Definitions and endpoints
Patients were divided into 3 groups according to the type
of oral hypoglycemic medications received: 1) patientsreceiving DPP4i either alone or in combination with any
other oral hypoglycemic medications, 2) patients receiving
metformin either as monotherapy or in combination with
other oral hypoglycemic medications (excluding DPP4i),
and 3) other oral hypoglycemic medications, excluding
DPP4i and Metformin.
Composite endpoints included: in-hospital complica-
tion (one or more of either acute renal failure, pulmon-
ary edema, infection, killip ≥ 2 on admission) [10] and
30-day MACE (one or more of either stent thrombosis,
urgent revascularization, post event ischemia, 30 day
mortality, re-infarction or re-ischemia, re-admission and
stroke/TIA), In-hospital and 30-day outcome data were
ascertained by hospital chart review, telephone contact,
and clinical follow-up data. Mortality data during
hospitalization and at 30 days were determined for all
patients from hospital charts and by matching identifica-
tion numbers of patients with the Israeli National Popu-
lation Register.
Statistical analysis
Baseline characteristics including risk factors, clinical
characteristic, laboratory values, hospital and 30-day
course of the patients were compared by the prespecified
three oral hypoglycemic treatment groups. Comparison
of categorical variables was performed with Chi-square
analysis and comparison of continuous variables was
performed with the nonparametric Wilcoxon rank-sum
and Kruskal-Wallis tests as appropriate. A logistic re-
gression model was used to evaulate the effect of dia-
betes treatment on the in-hospital and 30-day composite
outcome measures. Prespecified covariates in the multi-
variate models included the baseline diabetes treatment
groups (using the other oral treatment [group 3] as the
referemce group), age, gender, history of CHF, history of
renal failure, history of peripheral vascular disease, his-
tory of hypertension, history of dyslipidemia and history
of ischemic heart disease. Odds ratios with 95% confi-
dence intervals were calculated using other oral treat-
ment (group 3) as the referemce group.
The statistical software used for the analyses was SAS
version 9.2 (SAS institute, Cary, North Carolina). A two-
sided p-value <0.05 was used for declaring statistical
significance.
Results
Of the 2193 patients enrolled in the 2010 ACSIS survey,
877 patients had diabetes (39.9%) on admission. Of the pa-
tients with diabetes on admission, 432 were excluded from
the analysis because: 1) data on hypoglycemic treatment
was missing from 217 cases, 2) 199 were treated with in-
sulin prior to admission (either as monotherapy or in
combination with oral hypoglycemic medications) and 3)
13 patients had diabetes mellitus type 1. Four hundred
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exclusion criteria and comprised the present study popu-
lation: representing 20.3% of the entire database and
50.7% of the diabetes sub-population. The mean age of
the patients included in this analysis was 67.8 years and
320 (71.9%) were males.
Clinical presentation and in-hospital management by oral
hypoglycemic treatment group
Of the 445 patients, 31 patients (7%) were included in
the DPP4 inhibitors group (DPP4i), 348 patients (78%)
in the metformin group and 66 patients (15%) received
other hypoglycemic medications, and were included in
the “other oral” group. Patients in the “other oral” group
were older with higher rates of chronic renal failure and
PVD (Table 1). No significant difference was noted




Age (years) 64.3 ± 9.7
Male sex (%) 84
* BMI (kg/m2) 30.1 ± 4.4
Co-morbidities
† Prior MI (%) 41.9
‡ Prior PCI (%) 51.6
§ Prior CHF (%) 9.7
|| Prior CRF (%) 22.6
¶ Prior PVD (%) 16.1




Admission laboratory parameters and values
* Admission SBP (mmHg) 150 ± 28
† Admission DBP (mmHg) 83 ± 16
Admission heart rate (bpm) 80 ± 20
‡ Maximal CK (IU/L) 121.5 (23–1994)
Glucose (mg/dL) 195 (111–429)
Leukocytes (cmm3x1000) 10.4 ± 3.7
§ LDL-c (mg/dL) 86 ± 27
Creatinine (mg/dL) 1.0 (0.5–2.3)
Admission KILLIP >1 (%) 9.7
*BMI – Body Mass Index.
§CHF – Congestive Heart Failure.
||CRF – Chronic Renal Failure.
†MI – Myocardial infarction.
‡PCI – Percutaneous Coronary Intervention.
¶PVD – Peripheral Vascular Disease.dataset, Sitagliptin was the only DPP4 inhibitor pre-
scribed to the patients, either as monotherapy, or in
combination with other medications. There was no sig-
nificant difference in blood pressure values and LDL-
cholsterol levels; However, patients on Metformin
tended to have a lower fasting plasma glucose on admis-
sion, whereas patients in the “other oral” group had a
higher creatinine level, associated with increased rate of
chronic renal failure. In addition, treatment with DPP4
inhibitors was associated with a lower admission KILLIP
class, as compared to the “metformin” and “other oral”
groups (Table 1). There were no statistically significant
differences in the rate and type of coronary reprerfusion
treatment for ST-elevation ACS (26.3% of patient popu-
lation) across the three treatment groups, nor were there
any differences noted in the in-hospital medication and
intervention treatment (Table 2).g to treatment group
Metformin Other oral p Value
n = 348 n = 66
67.3 ± 11.3 72.2 ± 12.9 0.001
71 70 0.30










144 ± 29 144 ± 32 0.68
81 ± 17 77 ± 16 0.13
82 ± 19 85 ± 22 0.41
167.0 (11–1994) 218.0 (41–1808) 0.20
159 (71–792) 189 (40–506) 0.09
10.7 ± 4.3 10.9 ± 4.2 0.82
90 ± 34 84 ± 30 0.58
1.0 (0.5–7.6) 1.4 (0.7–6.5) <0.001
16.4 34.8 <0.001
Figure 1 Acute coronary event type by treatment group.
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treatment group
Type of coronary event varied: 26.3% of the patients
were diagnosed with a STEMI, 40.9% with a non-STEMI
and 32.8% with UAP. There was no difference in the
prevalence of the type of coronary event through the
treatment groups (Figure 1).
The rate and number of in hospital complications and
30-day major cardiovascular events are specified in
Figure 2. Rates of pulmonary edema, acute renal failure
and infections during hospitalizations were higher in the
other oral group as compared to the DPP4i and metfor-
min groups (p = 0.01, 0.003, 0.0009 respectivly). When
comparing specific 30-day MACE events, the occurrence
of unstable AP tended to be higher in the other oral
group (p = 0.06) compared to the DPP4i group. In
addition, length of stay varied across treatment groups.
Median length of stay was 5 days (3–7 days for Q1-Q3)
in the DPP4i group, 4 days [3-7] in the Metformin group
and 6 days [3-10] in the Other Oral group (p = 0.02).
When analysing the composite of in-hospital compli-
cations, type of diabetes treatment was a significant con-
tributor to the complication rate. Multivariate logistic
regression analysis (see Methods) revealed that treatment
with DPP4i (OR = 0.21, 0.05–0.87) were independently as-
sociated with a lower risk for in-hospital complications.
Other variables associated with in-hospital complications
were: prior CHF (OR = 3.2, 95% confidence interval 1.72–
5.95) and age (1 year increment) (OR = 1.08, 1.06–1.11)





* LMW Heparin (%) 48.4
† UF Heparin (%) 46.7
‡ ACE Inhibitors (%) 76.7
§ ARB (%) 10.0
Beta Blockers (%) 87.1
Statins 93.5
Coronary interventions during admission
STEMI reperfusion (%) 71
|| PCI (%) 70.4
Coronary stenting (%) 88.9
Coronary bypass Surgery (%) 11.1
‡ACEIs – Angiotensin Converting Enzyme.
§Angiotensin Receptor Blockers.
*LMW – Low Molecular Weight.
||PCI – Percutaneous Coronary.
Intervention.
†UF – UnfractionatedMACE endpoint was also significantly influenced by dia-
betes treatment. Multivariate logistic regression models
(see Methods) revealed that DPP4i treatment was inde-
pendently associated with lower composite 30-day MACE
(OR = 0.27, 0.08–0.96). Other parameters associated with
increased 30-day MACE were: CHF (OR= 3.02, 1.64–5.57)
and age (OR = 1.07, 1.04–1.09) (c for the model =0.769).
Discussion
Despite the beneficial effect of DPP4i on glucose levels
[11], the high number of substrates of the DPP-4 [12] raise
the question whether one substrate (or more) would have
negative effects to undermine the beneficial effects ofps
Metformin Other Oral p Value













Figure 2 Rate of in-hospital complications (panel A) and 30-day
major cardiovascular events (panel B) by treatment group
(Number of events appear at the base of each specific column).
For panel A, composite endpoint (compared to other oral) were:
0.129 (95% CI 0.036–0.465) for the DPP4i group and 0.388 (95% CI
0.225–0.667) for the Metformin group. For panel B, composite
endpoint (compared to other oral) were: 0.157 (95% CI 0.05–0.50) for
the DPP4i group and 0.491 (95% CI 0.288–0.837) for the Metformin
group. “*” indicates a p value of less than 0.05.
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documented by Jackson et al. [13,14], who showed that
treatment with Sitagliptin increased the renovascular ef-
fects of angiotensin II. This was attributed to enhanced
effect of peptide YY1-36, one of the substrate of the DPP-4
enzyme. The clinical singnificance of this finding is un-
known, however, tbe majority of the substrates are pep-
tides with little or no cardiovascular effect [12].
The main effect of DPP4i is associated with GLP-1.
Altough there are no randomized clinical studies on the
effect of GLP-1 on cadiovascular disease, treatment with
GLP-1 analogues may be associated with improved sta-
tus of cardiovascular risk factors such as hypertensionand body weight [15-17]. Besides the effects on CVD
risk factors, GLP-1 was found to have a beneficial effect
on infarct size in animal models [18], as well as among
diabetes patients undergoing CABG surgery, where the
untreated group required inotropic and vasoactive infu-
sions more frequently compared to those treated with
GLP-1 [19]. Altough the number of studies evaluating
the effects of DPP4i on CVD are limited, a beneficial ef-
fect of DPP4i treatment on blood pressure was observed
in a study of non diabetic population [20]. However, the
magnitude of blood pressure reduction was minimal.
Additional effects on atherosclerosis were found in a
model of LDL receptor knockout mice, as well as in
APOE knockout model, where DPP4i was associated
with less atherosclerosis. The effect is attributed to re-
duced monocyte assocaited inflammation [21] and aug-
mented effect of GLP-1 in macrophages and endothelial
cells [22].
Besides the effect of DPP4i on CVD risk factors and ath-
erosclerosis, an interesting and recent finding was the ef-
fect of DPP4i on endothelial progenitor cells (EPCs).
Circulating EPCs, originating from the bone marrow, have
the ability to differentiate into endothelial cells, and by
that play a key role in vasculogenesis [23]. In the cardio-
vascular system, the amount of circulating EPCs predicts
the occurrence of cardiovascular events and death from
cardiovascular causes [24]. Fadini et al. showed recently
that DPP4i enhances the level of circulating EPCs [25].
Our study showed a beneficial association between
pre-treatment with DPP4i and short-term cardiovascular
outcomes among patients admitted with acute coronary
syndrome. Alongside the history of CHF and age,
chronic treatment with Sitagliptin, the only DPP4i given
in our study population, was associated with a better
KILLIP class on admission and reduced rates of 30-day
MACE. Similar results were reported recently by Engel
et al., which showed reduced incidence of CVD end-
points among diabetes patients treated with Sitagliptin
compared to ones treated with sulphonyl-urea [26].
Moreoever, we documented additional lower rates of in-
hospital complications (i.e. acute renal failure and pul-
monary edema) with DPP4i treatment. This can be a
random finding due to the small number of events, but
it may also represent possible additional effects of DPP4
inhibition, such as the effect on endothelial dysfunction
and inflammation [27].
It shoud be noted that Sitagliptin was the only DPP4
inhibitor that was presscribed in our dataset. Despite the
similar mechanism of action, DPP4 inhibitors are not
necessarily identical, and have pharmaco-dynamic and
pharmaco-kinetic properties [28]. This was also shown to
have clinical ramifications in a recent study, which showed
that the mean amplitude of glycemic excursions, highest
blood glucose level after supper, and hyperglycemia after
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compared to once daily sitagliptin [29]. This question
should be answered with randomized controlled trials that
would be published in the near future.
Study limitations
As all retrospective analysis, one cannot conclude a dir-
ect effect of DPP4i on cardiovascular events, and only
the on-going randomized studies could give a direct an-
swer to this question. The small sample size in the
DPP4i group and the fact that treatment duration was
not recorded may increase the chances that the findings
are accidental and could be randome. the In addition,
our survey was not designed to be a study for diabetics,
and therefore the status of the disease, the rate of con-
trol as well as the duration are not available.
In conclusion, our data from ACSIS 2010 suggest that
pre-treatment with DPP4i may be associated with a lower
risk of in hospital complications and 30-day MACE
among patients presenting with acute coronary syndrome.
These findings suggest a possible role for DPP4i in appro-
priately selected high-risk patients with diabetes mellitus.
Abbreviations
ACS: Acute Coronary Syndrome; ACSIS: Acute Coronary Syndrome Israeli
Survery; CHF: Congestive Heart Failure; CI: Confidence Interval; DPPi: Di
Pepidyl Peptidase 4 inhibitors; EPCs: Endothelial Progenitor Cells; GLP-
1: Glucose Like Peptide-1; MACE: Major Adverse Cardiovascular Events;
OR: Odds Ratio; STEMI: ST-Elevation Myocardial Infarction; UAP: Unstable
Angina Pectoris.
Competing interests
The authors declare that there are no competing interests.
Authors’ contributions
EL, SG, IG and DG designed the study. SG, IG, NGY and SM designed and
performed the statistical analysis. EL, SG, IG and DG drafted and reviewed
the manuscript. EL, SG and DG gave final approval of the manuscript. All
authors read and approved the final manuscript.
Acknowledgement
We are indebted to all the physicians and nurses who participated in the
ACSIS 2010.
Author details
1Department of Internal Medicine “A” Wolfson Medical Center, Holon, Israel.
2Neufled Cardiac Research Institute, Sheba Medical Center, Ramat Gan, Israel.
3Heart Institute, Bikur Cholim Campus, Cardiology Department, Shaare Zedek
Medical center, Jerusalem, Israel. 4Sackler Medical School, Tel Aviv University,
Tel Aviv, Israel.
Received: 8 January 2013 Accepted: 18 March 2013
Published: 28 March 2013
References
1. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of
diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4–14.
2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V,
Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg
R, Stitzel KF, Stone NJ: American heart association; American diabetes
association. Primary prevention of cardiovascular diseases in people with
diabetes mellitus: a scientific statement from the American heart
association and the American diabetes association. Circulation 2007,
115:114–126.3. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med 2007,
356:2457–2471.
4. Woodcock J, Sharfstein JM, Hamburg M: Regulatory action on
rosiglitazone by the U.S. Food and drug administration. N Engl J Med
2010, 363:1489–1491.
5. Kim JY, Lim DM, Moon CI, Jo KJ, Lee SK, Baik HW, Lee KH, Lee KW, Park KY,
Kim BJ: Exendin-4 protects oxidative stress-induced β-cell apoptosis
through reduced JNK and GSK3β activity. J Korean Med Sci 2010,
25:1626–1632.
6. Langley AK, Suffoletta TJ, Jennings HR: Dipeptidyl peptidase IV inhibitors
and the incretin system in type 2 diabetes mellitus. Pharmacotherapy
2007, 27:1163–1180.
7. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H: Sitagliptin
Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4
inhibitor sitagliptin as monotherapy in patients with type 2 diabetes
mellitus. Diabetologia 2006, 49:2564–2571.
8. Yazbeck R, Howarth GS, Abbott CA: Dipeptidyl peptidase inhibitors, an
emerging drug class for inflammatorydisease? Trends Pharmacol Sci 2009,
30(11):600–607.
9. Arbelle JE, Porath A, Cohen E, Gilutz H, Garty M: Israeli National Survey
Group on Acute Myocardial Infarction, 2000. Triage disposition of
patients with acute myocardial infarction–ACSIS 2000. Isr Med Assoc J
2003, 5:786–790.
10. Killip T, Kimball JT: Treatment of myocardial infarction in a coronary care
unit. A two year experience with 250 patients. Am J Cardiol 1967,
20:457–464.
11. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK:
Effect of sitagliptin on glucose control in adult patients with Type 1
diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med
2011, 28:1176–1181.
12. Chen X: Biochemical properties of recombinant prolyl dipeptidases DPP-
IV and DPP8. Adv Exp Med Biol 2006, 575:27–32.
13. Jackson EK, Mi Z: Sitagliptin augments sympathetic enhancement of the
renovascular effects of angiotensin II in genetic hypertension.
Hypertension 2008, 51:1637–1642.
14. Tofovic DS, Bilan VP, Jackson EK: Sitagliptin augments angiotensin II-
induced renal vasoconstriction in kidneys from rats with the metabolic
syndrome. Clin Exp Pharmacol Physiol 2010, 37:689–9.
15. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs
DG, Wintle ME: Metabolic effects of two years of exenatide treatment on
diabetes, obesity, and hepatic biomarkers in patients with type 2
diabetes: an interim analysis of data from the open-label, uncontrolled
extension of three double-blind, placebo-controlled trials. Clin Ther 2007,
29:139–153.
16. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter
L, DURATION-1 Study Group: Exenatide once weekly versus twice daily for
the treatment of type 2 diabetes: a randomised, open-label, non-
inferiority study. Lancet 2008, 372:1240–1250.
17. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H,
Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B: LEAD-3 (mono) study
group. Liraglutide versus glimepiride Monotherapy for type 2 diabetes
(LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-
treatment trial. Lancet 2009, 373:473–481.
18. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like
peptide 1 can directly protect the heart against ischemia/reperfusion
injury. Diabetes 2005, 54:146–151.
19. Müssig K, Oncü A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G,
Häring HU, Holst JJ, Gallwitz B: Effects of intravenous glucagon-like
peptide-1 on glucose control and hemodynamics after coronary artery
bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008,
102:646–647.
20. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA,
Herman GA, Herman GA: Effect of sitagliptin, a dipeptidyl peptidase-4
inhibitor, on blood pressure in nondiabetic patients with mild to
moderate hypertension. J Clin Pharmacol 2008, 48:592–598.
21. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B,
Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S:
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and
inflammation via effects on monocyte recruitment and chemotaxis.
Circulation 2011, 124:2338–2349.
Leibovitz et al. Cardiovascular Diabetology 2013, 12:53 Page 7 of 7
http://www.cardiab.com/content/12/1/5322. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E,
Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K,
Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H: A
dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves
endothelial function and reduces atherosclerotic lesion formation in
apolipoprotein E-deficient mice. J Am Coll Cardiol 2012, 59:265–276.
23. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M,
Magner M, Isner JM, Magner M, Isner JM: Bone marrow origin of
endothelial progenitor cells responsible for postnatal vasculogenesis in
physiological and pathological neovascularization. Circ Res 1999,
85:221–228.
24. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig
G: Circulating endothelial progenitor cells and cardiovascular outcomes.
N Engl J Med 2005, 353:999–1007.
25. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S,
Agostini C, Tiengo A, Avogaro A: The oral dipeptidyl peptidase-4 inhibitor
sitagliptin increases circulating endothelial progenitor cells in patients
with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Diabetes Care 2010, 33:1607–1609.
26. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ:
Cardiovascular safety of sitagliptin in patients with type 2 diabetes
mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3.
27. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K,
Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa
H: Dipeptidyl peptidase-4 inhibitor. Improves endothelial dysfunction in
association with its anti-inflammatory effects in patients with coronary artery
disease and uncontrolled diabetes. Sitagliptin: Circ J; 2013 [Epub ahead of
print].
28. Duez H, Cariou B, Staels B: DPP-4 inhibitors in the treatment of type 2
diabetes. Biochem Pharmacol 2012, 83:823–832.
29. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K:
Comparison of vildagliptin twice daily vs. sitagliptin once daily using
continuous glucose monitoring (CGM): crossover pilot study
(J-VICTORIA study). Cardiovasc Diabetol 2012, 11:92.
doi:10.1186/1475-2840-12-53
Cite this article as: Leibovitz et al.: Sitagliptin pretreatment in diabetes
patients presenting with acute coronary syndrome: results from the
Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovascular
Diabetology 2013 12:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
